Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong.
David Tak Wai LuiEric Ho Man TangTingting WuIvan Chi Ho AuChi Ho LeeYu Cho WooKathryn Choon Beng TanCarlos King-Ho WongPublished in: Cardiovascular diabetology (2023)
Our real-world study demonstrated that GLP-1RA use was associated with lower risk of ischemic stroke, despite the association between SGLT2i use and lower risk of incident AF. There was no significant difference in hemorrhagic stroke risk. GLP-1RA may be the preferred agent for patients with type 2 diabetes at risk of ischemic stroke.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- left atrial
- catheter ablation
- left atrial appendage
- rheumatoid arthritis
- direct oral anticoagulants
- heart failure
- percutaneous coronary intervention
- disease activity
- cardiovascular disease
- ankylosing spondylitis
- type diabetes
- human health
- systemic lupus erythematosus
- risk assessment
- blood brain barrier
- left ventricular